Navigation Links
AutoGenomics CYP 2C19 Test Used in Study to Personalize Clopidogrel (Plavix) Dosing in Patients
Date:1/22/2009

CARLSBAD, Calif., Jan. 22 /PRNewswire/ -- AutoGenomics, a leader in providing automated molecular testing solutions announced today that its CYP450 2C19 assay was used in a study to demonstrate the value of genetic variants in dosing of the antiplatelet agent, Plavix.

Plavix, commonly known as Clopidogrel, is an anti-platelet agent used in the treatment for coronary artery disease, peripheral vascular disease and cerebrovascular disease. To realize the antiplatelet effect, Clopidogrel requires biotransformation to an active metabolite by cytochrome P-450 enzymes.

"Personalizing Clopidogrel dosing using pharmacogenetics may be an effective method of rationalizing treatment. In a recent study we used the AutoGenomics 2C19 test to screen for polymorphisms associated with a reduced response to the drug" said Dr. Mark Webster, Director of Cardiac Catheterization at the Auckland City Hospital. His co-investigator Dr. Patrick Gladding said that "other studies have shown that patients treated with Clopidogrel with a reduced function CYP C219 genetic variant had lower levels of the active metabolite resulting in a reduced antiplatelet response to the drug and a three-fold risk of stent thrombosis."

"We are pleased that Dr. Webster and Dr. Gladding have taken a pioneering role in assessing the role of genetic variants in Clopidogrel dosing to ensure patient safety. The AutoGenomics platform enables the rapid testing of such CYP 450 tests including CYP 2C9, CYP 3A4 & CYP 3A5 that have been quoted in recent publications as factors that could be of interest in drug dosing" said Ramanath Vairavan, Senior Vice President at AutoGenomics. He further said "that recent studies published in the New England Journal of Medicine indicated that about 30% of the patients had at least one CYP 2C19 reduced function genetic variant". With such high incidence
'/>"/>

SOURCE AutoGenomics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. AutoGenomics Receives FDA Clearance for its INFINITI(TM) Warfarin Assay
2. AutoGenomics Receives a Key European Patent for HPV Detection
3. AutoGenomics INFINITI Analyzer Receives Artistic Design Award
4. AutoGenomics, Inc. Files Registration Statement for Initial Public Offering
5. Penn study finds pro-death proteins required to regulate healthy immune function
6. New study shows promise in reducing surgical risks associated with surgical bleeding
7. Study, meta-analysis examine factors associated with death from heatstroke
8. Study suggests loss of 2 types of neurons -- not just 1 -- triggers Parkinsons symptoms
9. Study says COPD testing is not measuring up
10. Preclinical study suggests organ-transplant drug may aid in lupus fight
11. Ability to cope with stress can increase good cholesterol in older white men, study finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... 01, 2014 The evolving healthcare ... community pharmacies. At ThoughtSpot 2014, AmerisourceBergen and Good ... practices and resources to enhance patient care and ... on critical issues to give independent pharmacists the ... , ThoughtSpot show attendance experienced a nearly ...
(Date:8/1/2014)... 1, 2014Lesbian, gay, bisexual, and transgender individuals who want ... as some of their heterosexual and cisgendered peers, such ... additional physiological and legal challenges to become parents. ... assisted reproduction options is presented in the article " ... published in LGBT Health , a ...
(Date:8/1/2014)... August 01, 2014 The American ... Gregg Harper (R-MS), and Peter Welch (D-VT), for ... Medicare Telehealth Parity Act of 2014, which improves ... this effort to improve healthcare access and affordability ... officer of ATA. "These cost-saving provisions are critical ...
(Date:8/1/2014)... 01, 2014 Market Publishers Ltd ... have been added to its catalogue. , ... Ingredients (APIs), Contract Research and Manufacturing Services (CRAMS), ... industry drivers include, among others, increasing ageing population, ... In 2015, the pharma market in India is ...
(Date:8/1/2014)... BEACH, FL (PRWEB) August 01, 2014 ... the 2014 California NextGen User Symposium in San Francisco, ... was held at the JW Marriott Union Square hotel. ... help practices get up to speed with ACA compliance ... earlier this month. The symposium provides attendees guidance with ...
Breaking Medicine News(10 mins):Health News:ThoughtSpot 2014 Inspires as General Session Concludes 2Health News:ThoughtSpot 2014 Inspires as General Session Concludes 3Health News:ThoughtSpot 2014 Inspires as General Session Concludes 4Health News:ThoughtSpot 2014 Inspires as General Session Concludes 5Health News:Advances in assisted reproduction create more options and new legal issues for LGBT couples 2Health News:ATA Applauds Bill on Medicare Telemedicine Improvements 2Health News:In-demand Markets Research Reports by Kelly Scientific Publications Now Available at MarketPublishers.com 2Health News:In-demand Markets Research Reports by Kelly Scientific Publications Now Available at MarketPublishers.com 3Health News:Quirk Healthcare Foundation Hosts Fifth Annual California NextGen User Symposium and Launches First Annual Florida NextGen User Symposium 2
... the supermarket as well as the drugs cupboard when it ... published in the October issue of IJCP, the International Journal ... ask their doctors whether they should apply honey to their ... is one of the oldest foods in existence and was ...
... (ANSA) Organizes Artists Sign-On Letter as Part of Center for Health ... ... ANGELES, Oct. 17 Last week, 39 celebrity activists,and Artists for a ... improve the President,s Emergency Plan for AIDS Relief,(PEPFAR). PEPFAR currently restricts 1/3 ...
... Hall,founder of The Hall Center in Santa Monica, CA, ... of her patients. It wasn,t until she became,immersed in ... investigating her birth control patients more carefully.,"I was shocked ... patients on the,pill, had hormone levels that were on ...
... DUBLIN, Calif., Oct. 17 SuperGen Inc.,(Nasdaq: ... discovery, rapid,development and commercialization of therapies for solid ... have,been accepted for poster presentations at the AACR-NCI-EORTC ... in San Francisco. The poster presentations will ...
... Bulletin Board: HFIT), a leading employee health improvement company,will ... 30,2007, on Monday, November 5, 2007, after the market ... conference call to discuss the results the,same day. Participating ... and,Chief Executive Officer, and Wes Winnekins, Chief Financial Officer. ...
... IRIDEX,Corporation (Nasdaq: IRIX ) announced today that ... Executive Officer, and as a member of,the Board of ... of,Directors has appointed Theodore A. Boutacoff, who is currently ... serve as the Company,s President,and Chief Executive Officer. Prior ...
Cached Medicine News:Health News:Patients should ask surgeons about using honey to heal wounds 2Health News:39 Noted Performing Artists Urge Congress to Fix Flaws in President's Global AIDS Plan 2Health News:Do Not Take the Pill! Dr. Prudence Hall Tells her Teen and Female Patients 2Health News:Do Not Take the Pill! Dr. Prudence Hall Tells her Teen and Female Patients 3Health News:SuperGen to Highlight Oncology Pipeline Data in Multiple Presentations at the AACR-NCI-EORTC International Conference 2Health News:SuperGen to Highlight Oncology Pipeline Data in Multiple Presentations at the AACR-NCI-EORTC International Conference 3Health News:Health Fitness Corp. to Report Third Quarter 2007 Financial Results on November 5, 2007 2
(Date:8/1/2014)... HILL, N.C. , Aug. 1, 2014  With ... is learning to speak a second language. Clinical efficacy ... new agencies established under the ACA like PCORI are ... With a variety of new entities and environments, the ... to speak the new language of outcomes and managed ...
(Date:8/1/2014)... -- In the latest call for gender equity in ... 60 doctors and leading medical experts from across the ... and Drug Administration,s (FDA) decision to approve 26 drugs ... dysfunction compared with ZERO for women,s most common complaint, ... by approving the first-ever drug to treat Hypoactive Sexual ...
(Date:8/1/2014)... 2014 According to the ... Closure, Anti infective), Basic (Films, Cleansing), Advanced (Hydrogels, ... Substitutes), Pressure Relief Devices, NPWT) - Global Forecast ... Market is expected to reach $18.3 Billion by ... a CAGR of 3.2% from 2014 to 2019. ...
Breaking Medicine Technology:Pharmaceuticals Learning the Language of the New Healthcare Landscape 2Pharmaceuticals Learning the Language of the New Healthcare Landscape 360+ Doctors and Leading Medical Experts Sign an Open Letter Urging the FDA to Approve First-Ever Drug to Treat Women's Most Common Form of Sexual Dysfunction, notes Even the Score 260+ Doctors and Leading Medical Experts Sign an Open Letter Urging the FDA to Approve First-Ever Drug to Treat Women's Most Common Form of Sexual Dysfunction, notes Even the Score 3Wound Care Market Worth $18.3 Billion by 2019 2Wound Care Market Worth $18.3 Billion by 2019 3
... to Four Years of Treatment Presented at ICAAC/IDSA,2008 ... (NYSE: SGP ) today reported a data ... demonstrated,sustained viral suppression and increased CD4 cell counts ... of therapy in treatment-experienced,HIV-infected patients. Vicriviroc was administered ...
... Pharmaceuticals, Inc. today,announced positive Phase 2 data for ... (AMC). The Phase 2 study compared,safety and efficacy ... 0796 to,Zyvox(R) in the treatment of patients with ... met its primary safety and,tolerability endpoint, demonstrating no ...
Cached Medicine Technology:Analysis of Long-Term Vicriviroc Data Provides Evidence of Sustained Viral Suppression, Increased CD4 Cell Counts and Tolerability in Treatment-Experienced HIV-Infected Patients 2Analysis of Long-Term Vicriviroc Data Provides Evidence of Sustained Viral Suppression, Increased CD4 Cell Counts and Tolerability in Treatment-Experienced HIV-Infected Patients 3Analysis of Long-Term Vicriviroc Data Provides Evidence of Sustained Viral Suppression, Increased CD4 Cell Counts and Tolerability in Treatment-Experienced HIV-Infected Patients 4Analysis of Long-Term Vicriviroc Data Provides Evidence of Sustained Viral Suppression, Increased CD4 Cell Counts and Tolerability in Treatment-Experienced HIV-Infected Patients 5Analysis of Long-Term Vicriviroc Data Provides Evidence of Sustained Viral Suppression, Increased CD4 Cell Counts and Tolerability in Treatment-Experienced HIV-Infected Patients 6Paratek Reports Positive Phase 2 Clinical Data on its New Antibiotic PTK 0796 in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy 2Paratek Reports Positive Phase 2 Clinical Data on its New Antibiotic PTK 0796 in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy 3Paratek Reports Positive Phase 2 Clinical Data on its New Antibiotic PTK 0796 in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy 4
... can be difficult for persons who have ... cord injuries and for children with poor ... other motor or coordination problems. The FoamWrap ... and coordination. Soft foam-lined material provides light ...
... a low profile contour at the palmar crease ... is an excellent choice to treat mild to ... or for wear following cast removal. The ... pile cinch fasteners provides support and compression to ...
... to treat DeQuervain's Tendonitis, strains and sprains ... advanced carpal tunnel syndrome and cumulative trauma ... Distal palmar crease contour allows for 90 ... Constructed from an open cell urethane ...
... is a solid, one-piece custom wrist orthotic designed to ... , ,Indications: , Wrist reconstruction , ... , Coles fracture - distal radius , ... , ORIF - Open reduction and internal ...
Medicine Products: